BRAEMS PHARMA CONSULTING: what changed
BRAEMS PHARMA CONSULTING
Largest movements
- Cash +€39,464
up €39,464 (+17.9%), from €220,687 to €260,151
mainly Net result for the year (+€50,137) and Receivables within one year (+€3,276)
- Receivables within one year -€3,276
down €3,276 (-16.2%), from €20,216 to €16,940
of which Trade receivables: -€3,275
- Deferred charges and accrued income +€3,270
up €3,270 (+300%), from €1,088 to €4,358
- Reserves +€50,137
up €50,137 (+46.7%), from €107,278 to €157,415
- Tax, wage and social debts -€11,264
down €11,264 (-21.7%), from €52,015 to €40,751
- Gross operating margin -€7,071
down €7,071 (-8.9%), from €79,228 to €72,157
- Taxes -€1,669
down €1,669 (-7.7%), from €21,656 to €19,986
Change in the result, 2024 to 2025
For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.
Derived cash bridge
The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €246,032 | €284,276 | +€38,244 | +15.5% |
| Fixed assets | 21/28 | €4,040 | €2,827 | -€1,213 | -30.0% |
| Tangible fixed assets | 22/27 | €4,040 | €2,827 | -€1,213 | -30.0% |
| Furniture and vehicles | 24 | €4,040 | €2,827 | -€1,213 | -30.0% |
| Current assets | 29/58 | €241,992 | €281,449 | +€39,457 | +16.3% |
| Amounts receivable within one year | 40/41 | €20,216 | €16,940 | -€3,276 | -16.2% |
| Trade receivables | 40 | €20,215 | €16,940 | -€3,275 | -16.2% |
| Other amounts receivable | 41 | €1 | - | -€1 | |
| Cash at bank and in hand | 54/58 | €220,687 | €260,151 | +€39,464 | +17.9% |
| Deferred charges and accrued income | 490/1 | €1,088 | €4,358 | +€3,270 | +300% |
| Total equity and liabilities | 10/49 | €246,032 | €284,276 | +€38,244 | +15.5% |
| Equity | 10/15 | €192,542 | €242,679 | +€50,137 | +26.0% |
| Contributions | 10/11 | €100 | €100 | = | 0.0% |
| Contributions outside capital | 11 | €100 | - | -€100 | |
| Other | 1109/19 | €100 | - | -€100 | |
| Reserves | 13 | €107,278 | €157,415 | +€50,137 | +46.7% |
| Distributable reserves | 133 | €107,278 | €157,415 | +€50,137 | +46.7% |
| Profit (loss) carried forward | 14 | €85,164 | €85,164 | = | 0.0% |
| Amounts payable | 17/49 | €53,490 | €41,597 | -€11,893 | -22.2% |
| Amounts payable within one year | 42/48 | €53,478 | €41,584 | -€11,894 | -22.2% |
| Trade debts | 44 | €1,463 | €832 | -€630 | -43.1% |
| Suppliers | 440/4 | €1,463 | €832 | -€630 | -43.1% |
| Taxes, remuneration and social security | 45 | €52,015 | €40,751 | -€11,264 | -21.7% |
| Taxes | 450/3 | €52,015 | €40,751 | -€11,264 | -21.7% |
| Accrued charges and deferred income | 492/3 | €12 | €13 | +€1 | +10.8% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €1,116 | €1,213 | +€97 | +8.7% |
| Other operating charges | 640/8 | €983 | €638 | -€345 | -35.1% |
| Gross operating margin | 9900 | €79,228 | €72,157 | -€7,071 | -8.9% |
| Operating profit (loss) | 9901 | €77,129 | €70,305 | -€6,823 | -8.8% |
| Financial charges | 65/66B | €415 | €182 | -€233 | -56.2% |
| Recurring financial charges | 65 | €415 | €182 | -€233 | -56.2% |
| Profit (loss) for the period before taxes | 9903 | €76,714 | €70,124 | -€6,590 | -8.6% |
| Income taxes | 67/77 | €21,656 | €19,986 | -€1,669 | -7.7% |
| Profit (loss) for the period | 9904 | €55,058 | €50,137 | -€4,921 | -8.9% |
| Profit (loss) for the period to be appropriated | 9905 | €55,058 | €50,137 | -€4,921 | -8.9% |
Next steps
Calculation and sources
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. Prepared on 7 November 2026 via checked.be.